Breaking Finance News

Bank of N.T. Butterfield & Son (CVE:NTB) target price raised to $32.00, reported today by Citigroup

Just yesterday Bank of N.T. Butterfield & Son (CVE:NTB) traded -6.63% lower at $25.61. Bank of N.T. Butterfield & Son’s 50-day moving average is $1.42 and its 200-day moving average is $1.37. The last closing price is up 23.21% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 47,971 shares of NTB traded hands, down from an average trading volume of 52,173

Bank of N.T. Butterfield & Son (CVE:NTB) had its price target upped to $32.00 by Citigroup in a report issued 10/11/2016. The bumped up target suggests a possible upside of 0.25% from the company's previous closing price.

Recent Performance Chart

Bank of N.T. Butterfield & Son (CVE:NTB)

Bank of N.T. Butterfield & Son has 52 week low of $1.08 and a 52 week high of $2.02 and has a market capitalization of $0.

Brief Synopsis On Bank of N.T. Butterfield & Son (CVE:NTB)

Neptune Technologies & Bioressources Inc. is a solution provider of omega-3's and other functional ingredients to branded marketers in the nutraceutical industry, primarily in North America. The Company is engaged in the development, manufacture and commercialization of marine-derived omega-3 fatty acids. The Company's products include Krill-Based Nutraceutical Products, including Neptune Krill Oil (NKO), OCEANO3, Formulations Derived from NKO and Neptune Krill Aquatein (NKA); Other Nutraceutical Products, and Pharmaceutical Product Candidate (CaPre)-Acasti. The Company's NKO is a marine oil extracted from krill (Euphasia superba). NKO consists of phospholipids, which contain omega-3 fatty acids, including eicosapentaenoic acid and docosahexaenoic acid (EPA & DHA), and antioxidants, such as astaxanthin, vitamin A and vitamin E. The Company sells OCEANO3 directly to consumers in Canada through its online platform (www.oceano3.com), under its brand name.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *